The envelope glycoprotein (gp7O) of a molecularly cloned, replication-defective feline leukemia virus (FeLV-FAIDS clone 61C) carries determinants for induction of fatal immunodeficiency disease, whereas the gp7O of its companion replication-competent, probably parent virus (clone 61E) does not. Immunoprecipitation analysis of the extracellular glycoproteins of 61E and EECC, a replication-competent viral construct composed of the 61C env and 3' long terminal repeat fused to the 61E gag-pol genes, demonstrated that the gp7O of EECC could be distinguished from that of 61E by both feline immune serum and a murine monoclonal antibody. Molecular weights of both the envelope precursor polyprotein (gp8O) and the mature extracellular glycoprotein (gp7O) of 61E were smaller than the corresponding proteins from the pathogenic EECC. Both the molecular weight disparity and monoclonal antibody discrimination of the two gp8Os were abolished by inhibition of envelope protein glycosylation with tunicamycin, whereas the apparent gp7O size differences were resolved by enzymatic removal of N-linked oligosaccharides. Pulse-chase studies in EECC-infected cells demonstrated that processing of gp8O to gp7O was delayed and that this retardation of envelope glycoprotein processing could be simulated in 61E-infected cells by treatment with the glucosidase inhibitor N-methyldeoxynojirimycin, a compound that causes retention of oligosaccharides in the high-mannose form. The resultant 61E gp7O then could be recognized by sera from EECC-immunized cats. The presence of a higher content of sialic acid on the apathogenic 61E gp7O indicated that oligosaccharides of 61E and EECC gp7O were processed differently. These data suggested that the unique biochemical properties which distinguish the envelope glycoproteins of the FeLV-FAIDS variant from its companion apathogenic parent virus were responsible for T-cell cytopathicity and induction of immunodeficiency disease. Further biochemical characterization of these glycoproteins should be useful in understanding the pathogenic mechanisms of immunodeficiency disease induced by retroviruses.
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Feline leukemia viruses (FeLV) induce a myriad of proliferative and degenerative diseases in naturally and experimentally infected cats. Perhaps the most significant pathogenic property of FeLVs, however, is induction of severe and progressive immunodeficiency. A recent FeLV isolate (FeLV-FAIDS), consistently induces fatal immunodeficiency disease characterized by severe lymphoid depletion, wasting syndrome, enteropathy, and opportunistic infections in infected animals (16, 29 day observation period. This virus can also infect (but is noncytopathic) feline T lymphocytes (E. A. Hoover et al., unpublished data). In contrast, the variant clone (61C), when rescued with 61E or employed as a construct (EECC) prepared by joining the 5' long terminal repeat (LTR) and the gag and pol regions of 61E with the env and the 3' LTR of 61C (30) reproduces the severe immunodeficiency syndrome seen with the original uncloned FeLV-FAIDS inoculum and is T-cell cytopathic in vitro.
Sequence analysis of the entire genome of the FeLV-FAIDS common form virus (4) and the env gene of the variant virus (30) has predicted that divergence at the nucleotide level of the 61C env should lead to a 6-amino-acid deletion near the amino terminal portion, a 6-amino-acid insertion near the carboxy terminus, and 11 scattered singleamino-acid changes in the extracellular glycoprotein of the pathogenic 61C variant compared with 61E. Sequence divergence of the 61E and 61C envelope genes and the association of pathogenicity with the 61C env-3' LTR region indicate that the envelope protein, gp7O, is a major effector of immunodeficiency and lymphocytopathicity.
Envelope glycoproteins are responsible for a variety of phenomena characteristic of retrovirus infection, including cell fusion (5, 24, 27, 31, 39) , both efficacious and detrimental induction of the host immune response (1, 2, 6, 15, 19, 20, 28) , and cellular transformation (Friend murine leukemia spleen focus-forming virus [23, 25, 26] and subgroup F avian leukosis virus [38] ). Many of these properties correlate with alterations in posttranslational modification of the proteins, including the rate of precursor processing (14, 40, 42) or the type of carbohydrate chains attached to the protein backbone (7, 12, 13, 27, 32, 36) . These posttranslational modifications are a function of both the protein primary structure and the repertoire of host cell processing enzymes (17, 18, 35) , either or both of which may influence the biological behavior of the viral envelope proteins.
In this report, we compare the envelope glycoproteins from the molecularly cloned, infectious but nonpathogenic FeLV-FAIDS common form virus (61E) with the pathogenic virus chimera (EECC), which contains the env gene and 3' LTR of variant 61C. We demonstrate that the genomic changes documented in the env gene result in antigenic, molecular weight, and processing differences in the pathogenic variant envelope glycoprotein compared with that of its apathogenic putative parent genome.
MATERIALS AND METHODS
Cells and viruses. Feline embryo fibroblasts (AH927), infected with cloned viruses or uninfected, were maintained at 37°C in 5% CO2 in Dulbecco minimum essential medium supplemented with 1% glutamine-1% penicillin-streptomycin-10% fetal calf serum.
Production of molecularly cloned parent virus, 61E, and construct EECC which contains the envelope and 3' LTR portion of the replication-defective, pathogenic 61C has been described previously (4, 30 Corp., Boston, Mass.) and were analyzed by fluorography. Purification of gp7O. Medium from 35S-labeled, infected cells was collected and clarified at 10,000 x g for 15 min, and the virus was pelleted at 100,000 x g for 1.5 h. Virus pellets were suspended in 0.025 M Tris (pH 7.8)-0.1 M NaCl-0.1% Triton X-100; the pellets were then vortexed and applied to an affinity column prepared with CNBr-activated Sepharose and monoclonal antibody C11D8 that recognizes a linear epitope in a conserved region of FeLV envelope proteins (11) . The column was extensively washed in this buffer and eluted with 4 M 4) and EECC (lane 5) . At this exposure, the p65 gag precursor band blends with that of the unglycosylated envelope polyprotein in lanes 6 and 7 which was precipitated with polyclonal anti-FeLV antibody.
evaluated by radioimmunoprecipitation assay, using antisera from virus-infected (61C) cats, goat anti-FeLV and anti-gp7O sera, and monoclonal antibodies produced against FeLV gp70 (11) . Most infected cats which succumb to immunodeficiency disease generate a poor anti-FeLV antibody response. However, cats 1755 and 1768 that were vaccinated intramuscularly with the cell-associated pathogenic defective variant (61C) produced antibodies that recognize only the EECC gp7O envelope glycoprotein (Fig. 1A, lanes 9 to  12) . Differential recognition of these two viral gp70s by the polyclonal (lanes 1 to 3) Fig. 1B , recapitulated the antigenic distinctness of these viral polyproteins. Thus, the envelope protein from EECC carries unique epitopes compared with the 61E gp7O, indicative of either divergence of primary structure, differences in posttranslational modifications, or both.
Analysis of envelope glycoproteins of 61E and EECC produced in tunicamycin-treated cells. The results in Fig. 1 also demonstrate that both gp8O and the mature glycoprotein gp7O from EECC run slightly slower on SDS-PAGE than do the corresponding proteins from 61E. Since the predicted overall length of the proteins is the same and gels were run under reducing conditions, the larger size of EECC glycoproteins could be due to differences in their carbohydrate contents. To evaluate this possibility, the glycoproteins were harvested from virus-infected cells grown in the presence of tunicamycin, a metabolic inhibitor that blocks the addition of N-linked sugars by preventing formation of an obligatory lipid-carbohydrate intermediate (22) . Immunoprecipitation of these proteins with polyclonal anti-FeLV antibody demonstrated that the unglycosylated precursor proteins from the two viruses had similar molecular weights as determined by SDS-PAGE ( Fig. 2A, lanes 6 and 7) . The pi5E epitope on the envelope polyprotein of 61E, previously inaccessible to monoclonal antibody C5E5, was exposed in the unglycosylated protein (see lanes 8 and 9). Serum from cat 1755, however, was unable to recognize the modified envelope protein from 61E ( Fig. 2A and B, lanes 4 and 5) . Thus, the oligosaccharide components appear to impose the molecular weight differences observed between the glycoproteins of EECC and 61E and to be responsible, in the case of C5E5 epitope recognition, for imparting a unique structure to the gp8O precursor glycoprotein.
Kinetics of envelope polyprotein processing in 61E-and EECC-infected cells. Lysates of EECC-infected cells labeled for 6 h or less contained a higher gp8O to gp7O ratio than did lysates of 61E-infected cells (see Fig. 1A, lanes 1 and 2) , suggesting that processing of the precursor envelope protein to gp7O and pi5E might be slower in EECC than in 61E-infected cells. Kinetics of gp8O processing in infected AH927 cells, as determined by pulse-chase experiment, are shown in Fig. 3 faster-migrating form at the earliest examined chase time of 30 min (data not shown). These results indicated that there is a delay in processing the EECC envelope precursor which might be due to failure of gp8O to undergo proper folding or glycosylation at an early stage of posttranslational processing.
Effect of M-DNJ on antigenic recognition and kinetics of processing of the envelope proteins from 61E and EECC. One of the early events in protein glycosylation is trimming of glucose and mannose residues from high-mannose oligosaccharides, a necessary step for further processing to complex carbohydrate chains (9, 41) . M-DNJ is a specific inhibitor of the glucosidases responsible for the first steps of this alteration (34) . If the apparent defect in processing of EECC gp8O results from omission of these cleavage steps, then it can be theorized that metabolic inhibition of this step in 61E-infected cells might impart some of the antigenic and kinetic characteristics of the EECC gp8O to the envelope precursor of 61E. To test this hypothesis, a pulse-chase experiment was conducted on virus-infected cells in the presence of 1 mM M-DNJ. Figure 4 shows that the gp80s of 61E and EECC labeled during the 25-min pulse had molecular sizes of 94 and 96 kilodaltons, respectively. There were equivalent amounts of labeled gp8O, which represent the majority of the label remaining in both 61E-and EECC-infected cell lysates after 2.5 h. Untreated, infected cell lysates were included at 2.5 h for comparison. Lanes 7 to 10 show lysates of a 6-h label of infected cells precipitated with anti-FeLV or serum from cat 1755. Retention of label in the 61E precursor glyroprotein was still evidence at this time. Furthermore, serum from cat 1755 precipitated gp8O from both viruses. These results indicate that defective modification of the precursor oligosaccharide side chains of EECC may confer the antigenic and kinetic properties that distinguish it from its nonpathogenic parent, 61E. Glycosidase digestion of purified gp7O of 61E and EECC. Alterations in the envelope precursor of 61E and the pathogenic construct EECC should be reflected in the mature envelope protein from these two viruses. To investigate this possibility, gp70 from 61E and EECC was purified and digested with specific glycosidase enzymes. Because EECC produces an abundance of non-virion-associated gp7O, a property of several retroviruses (3, 33, 37) , this soluble form of the envelope protein also was purified and compared with the virion-associated gp70 of 61E and EECC. Figure 5 shows the results of this analysis. As was predicted by the tunicamycin studies, complete removal of N-linked oligosaccharides by digestion with N-glycanase negated the differences in molecular weight observed in the native proteins. Removal of sialic acid residues, however, accentuated this molecular weight difference, causing 61E gp7O to migrate faster than the neuraminidase-treated protein from EECC. These findings are consistent with the observation that interference in processing of high-mannose to complex carbohydrates in the EECC envelope precursor protein results in biochemical distinction of the mature envelope glycoprotein, gp70. (40) . In other retrovirus systems, defective cleavage due either to amino acid changes at the gp7O-pl5E cleavage site or to changes in oligosaccharide processing is associated with decreased infectivity and inability to establish interference (8, 32) . Similar to the aforementioned viruses, the FeLV-FAIDS pathogenic variant virus (61C) and its replication-competent viral construct (EECC) differ from the apathogenic parent virus (61E) in the structure, processing, and distribution of the envelope protein gp7O. Several mechanisms can be formulated to explain the altered biochemical properties of this glycoprotein and its role in cytopathology. Intracellular accumulation of gp8O in the internal membrane system may cause alteration in processing of a normal cellular glycoprotein essential for cell viability. In this situation, pathogenicity is due more to a mechanical blockage than to a specific effect of the virus. Conversely, delayed processing also leads to structural differences in the mature gp7O which is found either associated with virions or soluble in tissue culture supernatants. The presence of soluble gp7O may be due to specific glycosylation signals which target the protein for secretion, to a more labile interaction of gp7O with the transmembrane protein, or to disorderly assembly of virus particles with subsequent shedding of excess gp7O. Although we have not detected differences between the soluble and virion-associated forms of gp7O to date, we cannot yet conclude that they do not exist. Even if the soluble and virion-associated EECC glycoproteins are identical, the relative excess of soluble gp7O or a different conformation conferred as a result of being in solution and unassociated with its transmembrane anchor may endow this protein with different biochemical properties relative to its virion-associated counterpart. It is plausible, therefore, that either virionassociated or soluble gp7O may be the effector of lymphocyte killing induced by this virus, perhaps through competition with an essential growth factor for its receptor or through interference with receptor function.
Nucleotide sequence analyses of FeLV-FAIDS molecular clones 61C and 61E indicate that differences exist in the env gene, and viral construct data demonstrate that this gene carries the pathogenic determinants of the virus. Data presented here show that these genomic differences in 61C env result in production of an envelope glycoprotein which is distinguishable from the gp7O of the apathogenic probable parent virus 61E by altered kinetics of posttranslational processing, size, carbohydrate constituents, and antigenic recognition. Further biochemical analyses of these proteins 
